These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20044916)

  • 21. Multitarget Therapeutics for Neurodegenerative Diseases.
    Gabr MT; Yahiaoui S
    Biomed Res Int; 2020; 2020():6532827. PubMed ID: 32695817
    [No Abstract]   [Full Text] [Related]  

  • 22. Experimental therapeutics of neurodegenerative disorders: unmet needs.
    Shoulson I
    Science; 1998 Nov; 282(5391):1072-4. PubMed ID: 9804537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotection by tetracyclines.
    Domercq M; Matute C
    Trends Pharmacol Sci; 2004 Dec; 25(12):609-12. PubMed ID: 15530637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From stroke to neurodegenerative diseases: The multi-target neuroprotective effects of 3-n-butylphthalide and its derivatives.
    Huang L; Wang S; Ma F; Zhang Y; Peng Y; Xing C; Feng Y; Wang X; Peng Y
    Pharmacol Res; 2018 Sep; 135():201-211. PubMed ID: 30103000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Potential of Genipin in Central Neurodegenerative Diseases.
    Li Y; Li L; Hölscher C
    CNS Drugs; 2016 Oct; 30(10):889-97. PubMed ID: 27395402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The concept of neuroprotective agents as a treatment modulator in the development of brain diseases].
    Bordet R; Lestage P; Onteniente B;
    Therapie; 2007; 62(6):463-72. PubMed ID: 18316011
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of Morin in Neurodegenerative Diseases: A Review.
    Kataria R; Sobarzo-Sanchez E; Khatkar A
    Curr Top Med Chem; 2018; 18(11):901-907. PubMed ID: 29992884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic potential of thyreoliberin (TRH) and its analogues as antiepileptic and neuroprotective drugs].
    Jantas D
    Przegl Lek; 2010; 67(11):1179-85. PubMed ID: 21442973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Society for Neuroscience--34th annual meeting. Neurodegenerative disease and ion channel modulators. 23-27 October 2004, San Diego, CA, USA.
    Mackonochie M; Phillips T
    IDrugs; 2004 Dec; 7(12):1070-3. PubMed ID: 15599795
    [No Abstract]   [Full Text] [Related]  

  • 30. An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases.
    Giacoppo S; Galuppo M; Montaut S; Iori R; Rollin P; Bramanti P; Mazzon E
    Fitoterapia; 2015 Oct; 106():12-21. PubMed ID: 26254971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotection in progressive brain disorders.
    Djaldetti R; Lev N; Melamed E
    Isr Med Assoc J; 2003 Aug; 5(8):576-80. PubMed ID: 12929297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Society for Neuroscience--34th annual meeting. Neuroprotection and anxiety. 23-27 October 2004, San Diego, CA, USA.
    Phillips T; Mackonochie M
    IDrugs; 2004 Dec; 7(12):1074-6. PubMed ID: 15599796
    [No Abstract]   [Full Text] [Related]  

  • 33. Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences.
    Cappelletti G; Cartelli D; Christodoulou MS; Passarella D
    Curr Pharm Des; 2017; 23(5):784-808. PubMed ID: 27981911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural polyphenols against neurodegenerative disorders: potentials and pitfalls.
    Ebrahimi A; Schluesener H
    Ageing Res Rev; 2012 Apr; 11(2):329-45. PubMed ID: 22336470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychopharmacological neuroprotection in neurodegenerative disease: heuristic clinical applications.
    Lauterbach EC; Shillcutt SD; Victoroff J; Coburn KL; Mendez MF
    J Neuropsychiatry Clin Neurosci; 2010; 22(2):130-54. PubMed ID: 20463108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Turning down, but not off.
    Lipton SA
    Nature; 2004 Apr; 428(6982):473. PubMed ID: 15057811
    [No Abstract]   [Full Text] [Related]  

  • 37. [Neuroprotective approaches in neurology - dashed hopes?].
    Zipp F
    Drug Res (Stuttg); 2013 Nov; 63 Suppl 1():S12-3. PubMed ID: 24242029
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
    Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An overview of the pathophysiology of neurodegenerative disorders.
    Willner C
    Altern Ther Health Med; 2004; 10(4):26-34; quiz 35, 96. PubMed ID: 15285272
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.